Active	Status	Sponsor type	Region	Phase	Filter
2 Active 4 Inactive 6 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Kimura, Kiminori
NCT06144086: A Phase 2 Trial of Foscenvivint in Liver Cirrhosis Patients Caused by HIV/HCV Co-infection With Hemophilia (OP-724-H201)	Active, not recruiting	2	6	Japan	Foscenvivint, CBP-beta-catenin inhibitor, OP-724, PRI-724 (former name)	Kiminori Kimura, MD, Japan Agency for Medical Research and Development	Liver Cirrhosis	03/25	06/25
NCT04688034: Safety and Tolerability Study of OP-724 in Liver Cirrhosis Patients by HIV/HCV with Hemophilia.	Completed	1	5	Japan	OP-724, CBP-beta-catenin inhibitor, PRI-724 (former name)	Kiminori Kimura, MD, Japan Agency for Medical Research and Development, Ohara Pharmaceutical Co., Ltd.	Liver Cirrhosis	07/22	07/22
Aruga, Tomoyuki
No trials found
Oe, Miyabi
No trials found